Wyeth Holdings Corporation

American Cyanamid Company

Janssen Pharmaceutica Nv

Wyeth

Dana-farber-cancer Institute Inc.

Enzon Pharmaceuticals, Inc.

Lee Greenberger

Haiyin He

Sridhar Krishna Rabindran

Yixian Zhang

Peter J Connolly

Zhengxing Qu

James Elliott Bradner

Guozhang Xu

Shenlin Huang

Philip Frost

Christopher J Ott

Ronghua Li

Jeannene Butler

Angel R Fuentes-Pesquera

Kenneth R LaMontagne, Jr

Rajanikanth Bandaru

Tammy M Sadler

The disclosure relates to oligonucleotide compounds (oligomers) that target Myc mRNA in a cell, leading to reduced expression of Myc. Reduction of Myc expression is beneficial for the treatment of certain disorders, such as hyperproliferative disorders (e.g., cancer). The disclosure provides therapeutic compositions comprising oligomers and methods for modulating the expression of Myc using said oligomers, including methods of treatment.

LNA antisense oligonucleotides for the modulation of Myc expression

The present invention is directed to substituted pyrimidine compounds of formula (I): and forms thereof, their synthesis and use for treating a chronic or acute protein kinase mediated disease, disorder or condition.

Substituted pyrimidine kinase inhibitors

The present invention describes the use of fumitremorgin A, B and C and a series of diketopiperazines of Formula (I) to resensitize multidrug resistant (MDR) cancer cells to the cytotoxic effects of chemotherapeutic drugs.

Reversal of multidrug resistance in human colon carcinoma cells

This invention provides a method of treating or inhibiting an estrogen receptor positive carcinoma in a mammal in need thereof, which comprises providing said mammal with an effective amount of a combination of a rapamycin and an antiestrogen.

Method of treating estrogen receptor positive carcinoma

Growing community of inventors

Montclair, NJ, United States of America

Lee Greenberger